Johnson & Johnson – Product Pipeline Review

Global Markets Direct’s, ‘Johnson & Johnson – Product Pipeline Review – 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Johnson & Johnson, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Johnson & Johnson

The report provides overview of Johnson & Johnson including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Johnson & Johnson’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Johnson & Johnson’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Johnson & Johnson’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Johnson & Johnson

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Johnson & Johnson’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Johnson & Johnson Snapshot 8

Johnson & Johnson Overview 8

Key Information 8

Key Facts 8

Johnson & Johnson - Research and Development Overview 9

Key Therapeutic Areas 9

Johnson & Johnson - Pipeline Review 19

Pipeline Products by Stage of Development 19

Pipeline Products - Monotherapy 20

Pipeline Products - Combination Treatment Modalities 21

Pipeline Products - Partnered Products 22

Pipeline Products - Out-Licensed Products 25

Johnson & Johnson - Pipeline Products Glance 27

Johnson & Johnson - Late Stage Pipeline Products 27

Johnson & Johnson - Clinical Stage Pipeline Products 30

Johnson & Johnson - Early Stage Pipeline Products 34

Johnson & Johnson - Unknown Stage Pipeline Products 39

Johnson & Johnson - Drug Profiles 40

(canagliflozin + metformin hydrochloride XR) 40

bedaquiline fumarate 41

daratumumab 44

ustekinumab 48

bortezomib 51

golimumab 57

tipifarnib 60

(cobicistat + darunavir + emtricitabine + tenofovir alafenamide) 63

(naproxen sodium + sumatriptan succinate) 65

abiraterone acetate 67

canagliflozin 70

esketamine hydrochloride 72

fulranumab 75

guselkumab 78

imetelstat sodium 81

infliximab 84

JNJ-56021927 86

rivaroxaban 88

sirukumab 94

tapentadol hydrochloride IR 97

trabectedin 99

JNJ-54861911 105

(AL-335 + odalasvir + simeprevir) 107

AL-335 108

ALS-8176 109

Cell Therapy for HIV-1 Infection 110

CNTO-3157 111

CNTO-6785 112

erdafitinib 114

JNJ-39393406 116

JNJ-40411813 118

JNJ-42039556 119

JNJ-42847922 121

JNJ-49095397 123

JNJ-53718678 125

JNJ-56022473 126

JNJ-56914845 127

JNJ-872 129

odalasvir 131

ORM-12741 132

quisinostat hydrochloride 133

rilpivirine 135

siltuximab 138

sovaprevir 141

TMC-310911 143

toreforant tartrate 144

CNTO-2476 146

COVA-322 147

telaprevir 148

Vaccine for Prostate Cancer 152

ACH-3422 155

AL-794 156

ALS-8112 157

CNTO-7160 158

EVT-100 Series 159

EVT-103 160

JNJ-18038683 162

JNJ-38877618 164

JNJ-42721458 165

JNJ-47910382 166

JNJ-49122944 167

JNJ-54175446 168

JNJ-55375515 169

JNJ-55920839 170

JNJ-56136379 171

JNJ-61610588 172

JNJ-64052781 173

JNJ-757 174

JNJ-809 176

NVR-3778 177

RV-1162 179

RV-1729 180

TOP-1288 181

Small Molecules for Rhinovirus Infections 182

Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections 183

AL-516 184

CNTO-530 185

COVA-208 186

COVA-420 187

COVA-493 188

COVA-494 189

DiTU 190

flubendazole 192

Gene Therapy for Arteriosclerosis and Endothelial Dysfunction 194

JNJ-26070109 195

JNJ-26993135 196

JNJ-28307474 197

JNJ-28312141 198

JNJ-28610244 199

JNJ-31020028 200

JNJ-35815208 201

JNJ-375 202

JNJ-39729209 203

JNJ-39933673 204

JNJ-40279486 205

JNJ-40413269 206

JNJ-41477670 207

JNJ-42314415 208

JNJ-42905343 209

JNJ-46778212 210

JNJ-47965567 211

JNJ-5234801 212

JNJ-54416076 213

Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis 214

Monoclonal Antibody for Autoimmune Diseases 215

Nucleozin 216

Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases 217

Recombinant Protein-1 for Undisclosed Indication 218

Recombinant Protein-2 for Undisclosed Indication 219

Recombinant Proteins for Inflammatory and Autoimmune Diseases 220

RV-1088 221

S-961 222

Small Molecule to Inhibit Capsid Protein for Hepatitis B 223

Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia 224

Small Molecule to Inhibit FLT3 for AML 225

Small Molecule to Inhibit PDE10A for Schizophrenia 226

Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity 227

Small Molecules to Antagonize P2X7 for Central Nervous System 228

Small Molecules to Inhibit FMS for Rheumatoid Arthritis 229

Stem Cell Therapy for Type 1 and Type 2 Diabetes 230

VE-202 231

ALS-2135 232

Cellular Immunotherapy for Solid Tumors 233

Drugs for Cancer 234

Drugs for Prostate Cancer 235

influenza vaccine 236

LCTA-949 237

Peptides to Inhibit Ion Channel for Chronic Pain 238

Recombinant Protein for Inflammatory Bowel Diseases 239

Small Molecule to Inhibit cccDNA for Hepatitis B 240

Small Molecule to Inhibit Kinase for Autoimmune Diseases 241

Small Molecules for Central Nervous System Disorders 242

Small Molecules for Hepatitis B 243

Small Molecules for Lymphoma 244

Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer 245

Small Molecules to Antagonize CCR2 for Type II Diabetes 246

Small Molecules to Block Cav2.2 Channel for Chronic Pain 247

TMC-207 Back Up 248

VX-353 249

Biologics for Undisclosed Indication 250

JNJ-40346527 251

RV-6153 253

Johnson & Johnson - Pipeline Analysis 254

Johnson & Johnson - Pipeline Products by Target 254

Johnson & Johnson - Pipeline Products by Route of Administration 262

Johnson & Johnson - Pipeline Products by Molecule Type 263

Johnson & Johnson - Pipeline Products by Mechanism of Action 264

Johnson & Johnson - Recent Pipeline Updates 275

Johnson & Johnson - Dormant Projects 381

Johnson & Johnson - Discontinued Pipeline Products 386

Discontinued Pipeline Product Profiles 386

Johnson & Johnson - Company Statement 389

Johnson & Johnson - Locations And Subsidiaries 391

Head Office 391

Other Locations & Subsidiaries 391

Appendix 412

Methodology 412

Coverage 412

Secondary Research 412

Primary Research 412

Expert Panel Validation 412

Contact Us 412

Disclaimer 413

List of Tables

List of Tables

Johnson & Johnson, Key Information 18

Johnson & Johnson, Key Facts 18

Johnson & Johnson – Pipeline by Indication, 2016 20

Johnson & Johnson – Pipeline by Stage of Development, 2016 29

Johnson & Johnson – Monotherapy Products in Pipeline, 2016 30

Johnson & Johnson – Combination Treatment Modalities in Pipeline, 2016 31

Johnson & Johnson – Partnered Products in Pipeline, 2016 32

Johnson & Johnson – Partnered Products/ Combination Treatment Modalities, 2016 33

Johnson & Johnson – Out-Licensed Products in Pipeline, 2016 35

Johnson & Johnson – Out-Licensed Products/ Combination Treatment Modalities, 2016 36

Johnson & Johnson – Pre-Registration, 2016 37

Johnson & Johnson – Filing rejected/Withdrawn, 2016 38

Johnson & Johnson – Phase III, 2016 39

Johnson & Johnson – Phase II, 2016 40

Johnson & Johnson – Phase I, 2016 42

Johnson & Johnson – IND/CTA Filed, 2016 44

Johnson & Johnson – Preclinical, 2016 45

Johnson & Johnson – Discovery, 2016 48

Johnson & Johnson – Unknown, 2016 49

Johnson & Johnson – Pipeline by Target, 2016 264

Johnson & Johnson – Pipeline by Route of Administration, 2016 272

Johnson & Johnson – Pipeline by Molecule Type, 2016 273

Johnson & Johnson – Pipeline Products by Mechanism of Action, 2016 274

Johnson & Johnson – Recent Pipeline Updates, 2016 285

Johnson & Johnson – Dormant Developmental Projects,2016 391

Johnson & Johnson – Discontinued Pipeline Products, 2016 396

Johnson & Johnson, Subsidiaries 401

List of Figures

List of Figures

Johnson & Johnson – Pipeline by Top 10 Indication, 2016 20

Johnson & Johnson – Pipeline by Stage of Development, 2016 29

Johnson & Johnson – Monotherapy Products in Pipeline, 2016 30

Johnson & Johnson – Combination Treatment Modalities in Pipeline, 2016 31

Johnson & Johnson – Partnered Products in Pipeline, 2016 32

Johnson & Johnson – Out-Licensed Products in Pipeline, 2016 35

Johnson & Johnson – Pipeline by Top 10 Target, 2016 264

Johnson & Johnson – Pipeline by Top 10 Route of Administration, 2016 272

Johnson & Johnson – Pipeline by Top 10 Molecule Type, 2016 273

Johnson & Johnson – Pipeline Products by Top 10 Mechanism of Action, 2016 274

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared